# Aclaris Therapeutics, Inc. (ACRS) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_973c76ac0057b4c0b805 · retrieved 2026-08-12T07:24:41.644Z

## Overview
Aclaris Therapeutics, Inc. is a pharmaceutical company that develops and commercializes dermatological and other therapeutic products.

Aclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement on August 6, 2026, with Leerink Partners LLC and Cantor Fitzgerald & Co. as sales agents for an at-the-market (ATM) offering of common stock. The agreement amends and restates the prior agreement dated February 27, 2025, which had provided for up to $100.0 million in common stock sales. Under the amended agreement, the Company may offer and sell shares at its sole discretion through the agents, who will use commercially reasonable efforts to place shares based on the Company's instructions. The Company will pay the agents a commission equal to 3.0% of the gross sales proceeds of any common stock sold under the agreement.

## Terms
- Counterparty: Leerink Partners LLC and Cantor Fitzgerald & Co. · Consideration: stock

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001104659-26-092128): 8-K - Aclaris Therapeutics, Inc. — *Aclaris Therapeutics, Inc. is a pharmaceutical company that develops and commercializes dermatological and other therapeutic products.* Aclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement on August 6, 2026, with Leerink Partners LLC and Cantor Fitzgerald & Co. as sales agents for an at-the-market (ATM) offering of common stock. The agreement amends and restates the prior agreement dated February 27, 2025, which had provided for up to $100.0 million in common stock sales. Under the amended agreement, the Company may offer and sell shares at its sole discretion through the agents, who will use commercially reasonable efforts to place shares based on the Company's instructions. The Company will pay the agents a commission equal to 3.0% of the gross sales proceeds of any common stock sold under the agreement.
  https://www.sec.gov/Archives/edgar/data/1557746/0001104659-26-092128.txt

## Citations
- 0001104659-26-092128 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926092128